Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France

Survival in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis in Five French Centers

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04282421

Acronym

SYMFASCT

Enrollment

Registered

2020-02-24

Start date

2007-01-01

Completion date

2020-02-01

Last updated

2020-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis

Keywords

allogeneic hematopoietic stem cell transplantation, survival, graft versus host disease

Brief summary

The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Detailed description

The allogeneic stem cell transplantation is the only curative treatment for myelofibrosis. However, because of complications such as infection, graft-versus-host disease and conditioning toxicity, this procedure is associated with a high morbidity-mortality rate. The discovery of molecular and genetic markers permitted to improve therapeutic strategy and survival of patient in the last few years. In this study, the investigators want to make an overview of survival, incidence of relapse and incidence of acute and chronic graft versus host disease in allogeneic stem cell transplantation for myelofibrosis, in five centers in France, between 2007 and 2017.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

adult patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis in five centers in France (Nancy, Besancon, Strasbourg, Pitie Salpetriere and Lyon) between 2007 and 2017 \-

Exclusion criteria

* age \< 18 years old

Design outcomes

Primary

Measure	Time frame	Description
survival	at 1 year	incidence of survival in the cohort

Secondary

Measure	Time frame	Description
incidence of relapse	at 1 year	incidence of relapse in the cohort
incidence of acute graft versus host disease	at 3 months	incidence of acute graft versus host disease in the cohort
incidence of chronic graft versus host disease	at 1 year	incidence of chronic graft versus host disease in the cohort

Outcome results